IL13RA2 and glioblastoma: For patients with GBM, a clinical study (NCT04003649) is evaluating the safety and feasability of a combination therapy of IL13Rα2-specific CAR T cells alone, or in combination with the immune check point inhibitors, nivolumab or ipilimumab.